+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Peripheral Neuropathic Pain Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768061
  • Report
  • 302 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Eli Lilly and Co
  • GL Pharm Tech Corp
  • GW Pharmaceuticals Plc
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • MORE
The global clinical trial report- “2019 Peripheral Neuropathic Pain Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Peripheral Neuropathic Pain. It presents in-depth analysis of Peripheral Neuropathic Pain clinical trials across markets and companies. The research work is for providing complete understanding into trends in Peripheral Neuropathic Pain.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Peripheral Neuropathic Pain clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Peripheral Neuropathic Pain

The research work is prepared through extensive and continuous research on Peripheral Neuropathic Pain trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Peripheral Neuropathic Pain patients are identified
  • The report includes panorama of Peripheral Neuropathic Pain clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Peripheral Neuropathic Pain clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Eli Lilly and Co
  • GL Pharm Tech Corp
  • GW Pharmaceuticals Plc
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Peripheral Neuropathic Pain Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Peripheral Neuropathic Pain Clinical Trials by Region
2.2.2 Average Enrollment of Peripheral Neuropathic Pain Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Peripheral Neuropathic Pain Treatment, 2019

3. Region wise Peripheral Neuropathic Pain Clinical Trials
3.1 Asia Pacific Peripheral Neuropathic Pain Clinical Trials by Country
3.2 Europe Peripheral Neuropathic Pain Clinical Trials by Country
3.3 North America Peripheral Neuropathic Pain Clinical Trials by Country
3.4 Middle East and Africa Peripheral Neuropathic Pain Clinical Trials by Country
3.5 South and Central America Peripheral Neuropathic Pain Clinical Trials by Country

4. Peripheral Neuropathic Pain Clinical Trial Trends
4.1 Start Year wise Peripheral Neuropathic Pain Clinical Trials
4.2 Phase wise Peripheral Neuropathic Pain Clinical Trials
4.3 Trial Status wise Peripheral Neuropathic Pain Clinical Trials
4.4 Trial Type wise Peripheral Neuropathic Pain Clinical Trials

5. Peripheral Neuropathic Pain Average Enrollment Trends
5.1 Average Enrollment in Peripheral Neuropathic Pain Trials by Year
5.2 Average Enrollment in Peripheral Neuropathic Pain Trials by Phase
5.3 Average Enrollment in Peripheral Neuropathic Pain Trials by Status
5.4 Average Enrollment in Peripheral Neuropathic Pain Trials by Type of Trial

6. Companies Participating in Peripheral Neuropathic Pain Clinical Trials
6.1 Peripheral Neuropathic Pain Trials by Sponsor Type
6.2 Peripheral Neuropathic Pain Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Peripheral Neuropathic Pain Trials- Phase 1
7.2 Peripheral Neuropathic Pain Trials- Phase 2
7.3 Peripheral Neuropathic Pain Trials- Phase 3
7.4 Peripheral Neuropathic Pain Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Peripheral Neuropathic Pain Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Figure 5: Europe - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Figure 7: North America - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Figure 9: Peripheral Neuropathic Pain Clinical Trials by Phase
Figure 10: Peripheral Neuropathic Pain Clinical Trials by Trial Status
Figure 11: Peripheral Neuropathic Pain Clinical Trials by Type
Figure 12: Peripheral Neuropathic Pain Clinical Trials by Sponsor Type
Figure 13: Peripheral Neuropathic Pain Clinical Trials by Leading Sponsors
Figure 14: Peripheral Neuropathic Pain Average Enrollment by Phase
Figure 15: Peripheral Neuropathic Pain Average Enrollment by Trial Status
Figure 16: Peripheral Neuropathic Pain Average Enrollment by Type
Figure 17: Peripheral Neuropathic Pain- Average Enrolment by Type of Sponsors
Figure 18: Peripheral Neuropathic Pain- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Peripheral Neuropathic Pain Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Table 5: Europe - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Table 7: North America - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Peripheral Neuropathic Pain Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Peripheral Neuropathic Pain Average Enrollment by Phase
Table 15: Peripheral Neuropathic Pain Average Enrollment by Trial Status
Table 16: Peripheral Neuropathic Pain Average Enrollment by Type
Table 17: Peripheral Neuropathic Pain- Average Enrolment by Type of Sponsors
Table 18: Peripheral Neuropathic Pain- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astellas Pharma Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Eli Lilly and Co
  • GL Pharm Tech Corp
  • GW Pharmaceuticals Plc
  • Intas Pharmaceuticals Ltd
  • Pfizer Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4768061
Adroll
adroll